This bill establishes the Native Children's Commission Implementation Act of 2026 to improve health, education, and safety outcomes for Native American, Alaska Native, and Native Hawaiian children and families. It creates several new advisory committees within federal agencies to provide ongoing guidance on issues such as juvenile justice, maternal health, substance abuse, and environmental protection. The legislation also authorizes grants and pilot programs to expand access to mental health services, increase the perinatal workforce, support Native language schools, and provide housing assistance for homeless youth and families. Additionally, it modifies existing laws to allow Tribes greater flexibility in administering nutrition and child care programs while ensuring they receive adequate funding for administrative costs.
The Maternal Access to Treatment Act of 2026 requires the Bureau of Prisons to offer medication-assisted treatment to pregnant inmates addicted to opioids. This provision ensures that pregnant women in federal custody have access to medical care for opioid use disorder, unless they explicitly choose to decline the treatment while remaining mentally competent. The bill directly affects the Bureau of Prisons and pregnant incarcerated women by mandating the availability of this specific medical service.
This bill creates a five-year pilot program to provide grants to states and local governments for expanding Forensic Assertive Community Treatment teams. These specialized teams offer intensive, round-the-clock support including mental health care, addiction treatment, and housing assistance to individuals with serious mental illness who are involved with the criminal justice system. The program requires teams to include a mix of psychiatrists, employment specialists, criminal justice partners, and peer specialists with lived experience. Additionally, the legislation authorizes funding for a study by the National Academies to evaluate the program's effectiveness and develop guidelines for scaling it up.
The Examining Opioid Treatment Infrastructure Act of 2026 directs the Comptroller General of the United States to conduct a study on the nation's capacity for treating opioid-use disorders. This evaluation will assess the availability of inpatient and outpatient programs, including detoxification, stabilization, and rehabilitation services, with specific attention to geographic gaps and needs for specific demographics like pregnant women and American Indians. The report will also examine the use of evidence-based treatments and identify barriers to reporting real-time overdose data. Ultimately, the bill aims to provide Congress with a comprehensive overview of current treatment resources and challenges within the healthcare system.
This bill strengthens the enforcement of mental health and substance use disorder parity rules under the Employee Retirement Income Security Act of 1974. It expands the scope of penalties to include plan sponsors, service providers, and administrators who fail to meet existing parity requirements, while also adding a specific category for genetic information violations. To support these enforcement efforts, the legislation appropriates $30 million annually from 2027 through 2031 to the Employee Benefits Security Administration. These changes apply to group health plans starting one year after the law is enacted.
The Medicaid RAC Improvement Act of 2026 strengthens oversight of the Medicaid Recovery Audit Contractor program to improve how states identify and recover improper payments. It requires the Centers for Medicare and Medicaid Services to establish clear expiration dates for state exceptions to the program, mandate detailed annual reports on audit results, and ensure managed care organizations are included in these reviews. Additionally, the bill directs the agency to study barriers preventing states from participating and to launch a five-year demonstration project aimed at increasing state engagement. The legislation also extends the standard audit period to allow reviews of payments made over the previous four fiscal years.
The Modernizing Opioid Treatment Access Act 2.0 of 2026 allows licensed addiction medicine specialists to prescribe methadone for opioid use disorder to be dispensed directly through pharmacies, rather than requiring patients to visit traditional treatment clinics. Under this bill, these practitioners must use electronic prescribing and can only dispense liquid or dispersible tablet formulations, while pharmacies do not need separate registration to handle these prescriptions. The law also permits telemedicine for maintenance or detoxification treatment and requires doctors to obtain informed consent from patients regarding how privacy protections differ between clinic and pharmacy settings. Additionally, the Attorney General can revoke a doctor's registration if a state requests it, and the Drug Enforcement Administration must report annually on the number of registered providers and pharmacies involved in the program.
The Residential Recovery for Seniors Act expands Medicare coverage to include three specific levels of residential treatment for substance use disorders: clinically managed low-intensity, clinically managed high-intensity, and medically managed services. To qualify for this coverage, facilities must meet strict standards regarding staffing, clinical assessments, and adherence to evidence-based criteria developed by recognized medical associations. The bill also establishes a new payment system that reimburses these facilities on a per-day basis, starting in fiscal year 2027, with rates initially set to cover 100% of their estimated costs.
The IBOGAINE Act aims to accelerate the development and approval of ibogaine and similar compounds for treating addiction, trauma, and serious mental illnesses by modifying federal drug laws. It creates a new voucher system that grants sponsors of breakthrough mental health drugs priority review by the FDA, while also establishing special registration rules to allow physicians to legally administer Schedule I substances to eligible patients under the "right to try" law. The legislation further directs the Department of Veterans Affairs to create a dedicated senior official and workforce plan for emerging therapies, mandates timely rescheduling of ibogaine from Schedule I to Schedule II, and requires federal agencies to share clinical trial data to speed up the approval process.
This Senate resolution designates June 6, 2026, as National Naloxone Awareness Day to highlight the importance of naloxone in reversing opioid overdoses. The measure aims to educate the public, healthcare providers, and first responders on how to recognize overdose signs and safely administer the medication. It also encourages federal, state, and local governments along with private organizations to support efforts that increase access to and distribution of naloxone.
